Skip to content

Study · Animal study (in vivo) · mouse · 2024

4 results

Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.

Wang RL, Yang ZH, Huang YY, Hu Y, Wang YL, Yan F, Zheng YM, Han ZP, Fan JF, Tao Z, Zhao HP, Li SJ, Luo YM

CNS neuroscience & therapeutics1 Mar 2024Cited by 8 (Europe PMC)

PMID38488446 (opens in a new tab)PMCIDPMC10941562 (opens in a new tab)DOI10.1111/cns.14676 (opens in a new tab)PepBankPUB-38488446
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

AimTo explore the neuroprotective effects of ARA290 and the role of β-common receptor (βCR) in a mouse model of middle cerebral artery occlusion (MCAO).MethodsThis study included male C57BL/6J mice that underwent MCAO and reperfusion. The neuroprotective effect of ARA290 on MCAO-induced brain injury was investigated using neurological function tests (Longa and modified neurological severity score). Cerebral infarction was examined by 2, 3, 5-triphenyl tetrazolium chloride staining, neuronal apoptosis was assessed by immunofluorescence staining, blood parameters were measured using a flow cytometry-based automated hematology analyzer, liquid chromatography with tandem mass spectrometry was used to identify the serum metabolomics signature, inflammatory cytokines and liver index were detected by commercially available kits, and the protein levels of the erythropoietin (EPO) receptor and βCR were measured by western blot.ResultsARA290 exerted a qualitatively similar neuroprotective effect after MCAO as EPO. ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue. However, ARA290's neuroprotective effect was significantly suppressed following the injection of siRNA against βCR.ConclusionARA290 provided a neuroprotective effect via βCR in cerebral ischemic mice without causing erythropoiesis. This study provides novel insights into the role of ARA290 in ischemic stroke intervention.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MCAO, ARA290 had a qualitatively similar neuroprotective effect to erythropoietin.

    In plain wordsIn mice with stroke, ARA290 protected the brain in a way similar to erythropoietin.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Direction not reportedNeuroprotective effect after MCAO
    Study

    mousen: not reported in source

    MCAO and reperfusion mouse model
    Comparator
    Erythropoietin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ARA290 exerted a qualitatively similar neuroprotective effect after MCAO as EPO.
    1 context sentence
    Summary · context
    This study included male C57BL/6J mice that underwent MCAO and reperfusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MCAO, ARA290 significantly reduced neuronal apoptosis in the brain.

    In plain wordsIn mice with stroke, ARA290 reduced the death of nerve cells in the brain.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNeuronal apoptosis
    Study

    mousen: not reported in source

    MCAO and reperfusion mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue.
    1 context sentence
    Summary · context
    This study included male C57BL/6J mice that underwent MCAO and reperfusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MCAO, ARA290 significantly reduced inflammatory cytokine levels in brain tissue.

    In plain wordsIn mice with stroke, ARA290 lowered inflammatory signals in the brain.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseInflammatory cytokines in brain tissue
    Study

    mousen: not reported in source

    MCAO and reperfusion mouse model
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue.
    1 context sentence
    Summary · context
    This study included male C57BL/6J mice that underwent MCAO and reperfusion.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with MCAO, the neuroprotective effect of ARA290 was significantly suppressed after siRNA against the β-common receptor.

    In plain wordsIn mice with stroke, silencing the β-common receptor weakened the brain protection by ARA290.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableRole of β-common receptor in neuroprotection
    Study

    mousen: not reported in source

    MCAO and reperfusion mouse model
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, ARA290's neuroprotective effect was significantly suppressed following the injection of siRNA against βCR.
    1 context sentence
    Summary · context
    This study included male C57BL/6J mice that underwent MCAO and reperfusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.